Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.71 |
| ▸ | HDAC1 | Q13547 | 7/20 | 0.68 |
| ▸ | HDAC8 | Q9BY41 | 7/20 | 0.68 |
| ▸ | HDAC6 | Q9UBN7 | 7/20 | 0.68 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.57 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.46 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1385110 | 0.91 | ALDH1A1 (0.60) | ALDH1A1HDAC1HDAC8HDAC6PDE4B | |
| SCHEMBL2560216 | 0.85 | HDAC1 (0.69) | ALDH1A1HDAC1HDAC8HDAC6PDE4B | |
| SCHEMBL27808017 | 0.85 | ALDH1A1 (0.73) | ALDH1A1HDAC1HDAC8HDAC6PDE4B | |
| SCHEMBL21689255 | 0.85 | ALDH1A1 (0.73) | ALDH1A1HDAC1HDAC8HDAC6PDE4B | |
| SCHEMBL28033118 | 0.83 | ALDH1A1 (0.71) | ALDH1A1HDAC1HDAC8HDAC6PDE4B | |
| SCHEMBL2222487 | 0.83 | HDAC1 (0.68) | ALDH1A1HDAC1HDAC8HDAC6PDE4B | |
| SCHEMBL893099 | 0.83 | ALDH1A1 (1.00) | ALDH1A1HDAC1HDAC8HDAC6PDE4B | |
| SCHEMBL27721487 | 0.81 | ALDH1A1 (0.73) | ALDH1A1HDAC1HDAC8HDAC6PDE4B | |
| SCHEMBL27786311 | 0.80 | ALDH1A1 (0.47) | ALDH1A1HDAC1HDAC8HDAC6PDE4B | |
| SCHEMBL2221957 | 0.80 | HDAC1 (0.67) | ALDH1A1HDAC1HDAC8HDAC6PDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2609091-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AS AXL INHIBITORS | Lead Discovery Center GmbH (DE) | 2013-07-03 | — | — | EP | claimed |
| WO-2012028332-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AS AXL INHIBITORS | LEAD DISCOVERY CENTER GMBH (DE) | 2012-03-08 | — | — | WO | claimed |
| EP-3829559-B1 | INHIBITORS OF HISTONE DEACETYLASE USEFUL FOR THE TREATMENT OR PREVENTION OF HIV INFECTION | MERCK SHARP & DOHME LLC (US) | 2026-05-13 | — | — | EP | disclosed |
| US-12331044-B2 | Inhibitors of histone deacetylase useful for the treatment or prevention of HIV infection | MERCK SHARP & DOHME LLC (US) | 2025-06-17 | — | — | US | disclosed |
| US-20210276992-A1 | INHIBITORS OF HISTONE DEACETYLASE USEFUL FOR THE TREATMENT OR PREVENTION OF HIV INFECTION | MERCK SHARP & DOHME CORP. (US) | 2021-09-09 | — | — | US | disclosed |
| US-20210276992-A1 | INHIBITORS OF HISTONE DEACETYLASE USEFUL FOR THE TREATMENT OR PREVENTION OF HIV INFECTION | MERCK SHARP & DOHME CORP. (US) | 2021-09-09 | — | — | US | disclosed |
| EP-3829559-A1 | INHIBITORS OF HISTONE DEACETYLASE USEFUL FOR THE TREATMENT OR PREVENTION OF HIV INFECTION | Merck Sharp & Dohme Corp. (US) | 2021-06-09 | — | — | EP | disclosed |
| WO-2020028150-A1 | INHIBITORS OF HISTONE DEACETYLASE USEFUL FOR THE TREATMENT OR PREVENTION OF HIV INFECTION | MERCK SHARP & DOHME CORP. (US) | 2020-02-06 | — | — | WO | disclosed |
| WO-2020028150-A1 | INHIBITORS OF HISTONE DEACETYLASE USEFUL FOR THE TREATMENT OR PREVENTION OF HIV INFECTION | MERCK SHARP & DOHME CORP. (US) | 2020-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12331044-B2 | Inhibitors of histone deacetylase useful for the treatment or prevention of HIV infection | HDAC1, HDAC11, HDAC10 | ALDH1A1 160/4885HDAC1 1/4885HDAC8 10/4885 |
| US-20210276992-A1 | INHIBITORS OF HISTONE DEACETYLASE USEFUL FOR THE TREATMENT OR PREVENTION OF HIV INFECTION | HDAC1, HDAC11, HDAC10 | ALDH1A1 160/4885HDAC1 1/4885HDAC8 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.